S N Levin1,2, T B Kaplan3,4. 1. Harvard Medical School, Boston, MA, USA. 2. Partners Multiple Sclerosis Center, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA. 3. Harvard Medical School, Boston, MA, USA. tbkaplan@partners.org. 4. Partners Multiple Sclerosis Center, Brigham and Women's Hospital, 45 Francis Street, Boston, MA, 02115, USA. tbkaplan@partners.org.
Abstract
PURPOSE OF REVIEW: Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system most often characterized by clinical relapses and periods of remission. RECENT FINDINGS: The past decade has seen a dramatic increase in disease-modifying therapies for MS. Fourteen FDA-approved immunomodulatory drugs are currently available, and more medications are in development. A growing number of reported opportunistic infections, including progressive multifocal leukoencephalopathy (PML), highlight the serious complications of these new drugs and the need for specific screening guidelines. Using data from Phase II and III randomized controlled trials, case reports, drug manufacturing data, and clinical experience, we outline the most common and serious infections associated with novel MS therapies.
PURPOSE OF REVIEW: Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system most often characterized by clinical relapses and periods of remission. RECENT FINDINGS: The past decade has seen a dramatic increase in disease-modifying therapies for MS. Fourteen FDA-approved immunomodulatory drugs are currently available, and more medications are in development. A growing number of reported opportunistic infections, including progressive multifocal leukoencephalopathy (PML), highlight the serious complications of these new drugs and the need for specific screening guidelines. Using data from Phase II and III randomized controlled trials, case reports, drug manufacturing data, and clinical experience, we outline the most common and serious infections associated with novel MS therapies.
Authors: Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts Journal: N Engl J Med Date: 2005-06-09 Impact factor: 91.245
Authors: Gavin Giovannoni; Ludwig Kappos; Ralf Gold; Bhupendra O Khatri; Krzysztof Selmaj; Kimberly Umans; Steven J Greenberg; Marianne Sweetser; Jacob Elkins; Peter McCroskery Journal: Mult Scler Relat Disord Date: 2016-05-11 Impact factor: 4.339
Authors: Eduardo F Mysler; Alberto J Spindler; Renato Guzman; Marc Bijl; David Jayne; Richard A Furie; Frédéric A Houssiau; Jorn Drappa; David Close; Romeo Maciuca; Kajal Rao; Saba Shahdad; Paul Brunetta Journal: Arthritis Rheum Date: 2013-09
Authors: C McGuigan; M Craner; J Guadagno; R Kapoor; G Mazibrada; P Molyneux; R Nicholas; J Palace; O R Pearson; D Rog; C A Young Journal: J Neurol Neurosurg Psychiatry Date: 2015-10-22 Impact factor: 10.154
Authors: David Baker; Samuel S Herrod; Cesar Alvarez-Gonzalez; Lukasz Zalewski; Christo Albor; Klaus Schmierer Journal: Neurol Neuroimmunol Neuroinflamm Date: 2017-06-05